Gadopiclenol vs Gadoxetate MRI for Liver Lesions
Part of paid clinical trials in New York, New York.
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Study ID
- NCT06596616
- Status
- Enrolling By Invitation
Conditions
- Liver Lesion
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 89 Years
- Healthy Volunteers
- Accepted
Interventions
- Radiology — OTHERRadiology - MRI Scans
- Gadopiclenol — OTHERGadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
Study Details
The overall purpose of this study is to establish noninferiority of gadopiclenol MRI compared to gadoxetate MRI in terms of image quality and lesion detection/conspicuity in patients undergoing clinically indicated liver MRI in a prospective study. The research will be utilizing MRI; with enrollment goal of 75 subjects over the course of two years.
Key Dates
- Start date
- Jul 1, 2024
- Status verified
- Apr 2026
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 23 participants (estimated)
Arms
- Arm: LiverPatients who have had clinically indicated MRI scans for liver lesions.
Primary Outcome Measure
Lesion Detection [ Time Frame: End of study, at 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| BMEII | New York | New York | 10029 | - |
Find similar trials in New York, NY
By research site